Drug Patent Watch

DECEMBER 19, 2024

A robust drug patent portfolio is not just an assetit’s a critical tool for success. As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. This comprehensive guide will explore how pharmaceutical companies can leverage their drug patent portfolios to maximize value, maintain market dominance, and drive innovation.

Drugs 54

Drugs Marketing Licensing Licensing 54

Pharmaceutical Technology

DECEMBER 19, 2024

MSD has entered an exclusive global licence agreement with Hansoh Pharma for a preclinical oral small molecule GLP-1RA.

258

258

Bio Pharma Dive

DECEMBER 19, 2024

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

Pharmacy 216

Pharmacy Marketing 216

Pharmaceutical Technology

DECEMBER 19, 2024

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Trials 147

Trials Drugs 147

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Bio Pharma Dive

DECEMBER 19, 2024

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.

Drugs 173

Drugs 173

Pharmaceutical Technology

DECEMBER 19, 2024

Mesoblast has gained US FDA approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil (remestemcel-L), to treat SR-aGvHD.

FDA Approval 147

FDA Approval 147

Pharmaceutical Technology

DECEMBER 19, 2024

BioAge Labs has entered a multi-year research partnership with Novartis to seek therapeutic drug targets for ageing-related conditions.

Drugs 147

Drugs Research 147

Bio Pharma Dive

DECEMBER 19, 2024

Even with another mid-stage setback, Roche believes there were enough positive signs to “merit further exploration” of the drug, which it’s been developing with Prothena for more than a decade.

Drugs 147

Drugs Development 147

Pharmaceutical Technology

DECEMBER 19, 2024

Novo Holdings has completed the previously announced acquisition of Catalent in an all-cash transaction valued at around $16.5bn.

147

147

Bio Pharma Dive

DECEMBER 19, 2024

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.

Medicine 147

Medicine Trials Marketing 147

Advertisement

Clinical Supply

Worldwide Clinical Trials

DECEMBER 19, 2024

At the recent World Orphan Drug Congresses (WODC) in Europe and the United States, Worldwide Clinical Trials Derek Ansel , Vice President, Therapeutic Strategy Lead, Rare Disease, facilitated roundtable discussions to explore the operational challenges and ethical barriers surrounding genetic testing. While the agenda remained the same across both events, the conversations revealed key regional distinctions and global perspectives on how genetic testing, ethics, and operational challenges are ad

Genetics 130

Genetics In-Vitro Drugs Clinical Trials 130

Bio Pharma Dive

DECEMBER 19, 2024

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

Development 147

Development Drugs 147

Pharmaceutical Technology

DECEMBER 19, 2024

In this issue: Recent US reproductive laws could limit womens participation in trials, how Pfizer outplayed Starboard, PreP therapies come to the fore, and more.

Clinical Trials 130

Clinical Trials Clinical Trials Trials 130

XTalks

DECEMBER 19, 2024

Mental health problems represent a critical area of unmet need worldwide, affecting an estimated one in eight people globally, according to the World Health Organization (WHO). These issues carry substantial personal and societal costs, impacting daily life and productivity. In fact, mental health conditions are associated with a 10- to 25-year reduction in life expectancy , emphasizing the need for effective and accessible treatments.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Research 96

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

pharmaphorum

DECEMBER 19, 2024

Neuralink rival Precision Neurosciences raises $102m for its brain-computer interface tech, plus financings for Redesign, DeepLife, TG0 and Tuva.

98

98

XTalks

DECEMBER 19, 2024

The US Food and Drug Administration (FDA) has approved ensartinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, as a first-line treatment for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Ensartinibs approval, granted under the commercial name Ensacove, was awarded to Xcovery Holdings, a subsidiary of Chinas Betta Pharmaceuticals.

FDA Approval 95

FDA Approval Marketing Trials Drugs 95

pharmaphorum

DECEMBER 19, 2024

Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.

Antibody 98

Antibody Drugs 98

XTalks

DECEMBER 19, 2024

The US Food and Drug Administration (FDA) has rejected Johnson & Johnsons (J&J) application for a subcutaneous formulation of Rybrevant (amivantamab). J&J was seeking FDA approval for the subcutaneous version of Rybrevant, a bispecific antibody that targets the epidermal growth factor receptor (EGFR) and the MET receptor (also known as hepatocyte growth factor receptor, HGFR) for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Sales 97

Sales FDA Approval Licensing Licensing 97

Advertisement

Clinical Supply

pharmaphorum

DECEMBER 19, 2024

Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.

98

98

Fierce Pharma

DECEMBER 19, 2024

Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. | Following in the footsteps of Pfizer, Roche and Takeda, another ALK inhibitor has made its belated entry into the U.S. The FDA nod comes four years after its initial approval in China.

Pharma Companies 87

Pharma Companies Drugs 87

pharmaphorum

DECEMBER 19, 2024

A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data

Trials 97

Trials 97

Fierce Pharma

DECEMBER 19, 2024

The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lillys tirzepatide from its list of products that are in shortage. The agencys move means that compounding pharmacies will have to halt production of their knockoff versions of diabetes drug Mounjaro and obesity treatment Zepbound.

Pharmacy 103

Pharmacy Production Drugs 103

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

pharmaphorum

DECEMBER 19, 2024

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

FDA Approval 96

FDA Approval 96

Outsourcing Pharma

DECEMBER 19, 2024

Gilead teams up with Terray for AI-powered drug discovery, leveraging Terrays tNova platform to accelerate the development of innovative treatments through generative AI and lab experiments.

Drugs 56

Drugs Development Marketing 56

pharmaphorum

DECEMBER 19, 2024

Novo Holdings' $16.

83

83

Pharma Marketing Network

DECEMBER 19, 2024

Table of Contents Sr# Headings 1 Introduction: Understanding Pharma Brands 2 Top Pharma Brands and Their Strategies 3 Trends Transforming the Pharma Industry 4 Conclusion: Adapting to the Pharma Future Introduction: Understanding Pharma Brands Pharma brands are the cornerstones of the healthcare industry, serving as the bridge between groundbreaking innovation and patient care.

Branding 52

Branding Marketing Medicine Production 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

pharmaphorum

DECEMBER 19, 2024

Discover how implementing a healthy and effective search strategy, focusing on Google, can significantly boost growth and success for pharmaceutical brands.

Branding 59

Branding 59

Pharma Marketing Network

DECEMBER 19, 2024

Table of Contents Sr# Headings 1 Introduction: Why Social Media Matters in Healthcare 2 The Unique Challenges of Healthcare Social Media Marketing 3 Effective Social Media Strategies for Pharma Success 4 Conclusion: Elevating Your Social Media Game Introduction: Why Social Media Matters in Healthcare In todays fast-paced digital landscape, healthcare social media marketing has become a game-changer for pharma brands.

Marketing 52

Marketing Branding Compliance Pharma Companies 52

pharmaphorum

DECEMBER 19, 2024

Explore how small molecule-focused Contract Development and Manufacturing Organisations (CDMOs) are adapting to the impact of the Inflation Reduction Act (IRA), shifting legislative landscape, and changes in the investment landscape.

Manufacturing 59

Manufacturing Development 59

Pharma Marketing Network

DECEMBER 19, 2024

Table of Contents Sr# Headings 1 Introduction: Why Programmatic Advertising Matters 2 How Programmatic Advertising Works 3 Benefits for Pharma Marketing Strategies 4 Overcoming Challenges in Programmatic Advertising 5 Conclusion: Embracing the Future of Advertising Introduction: Why Programmatic Advertising Matters In the fast-paced world of digital marketing, programmatic advertising is changing the game for pharma marketers.

Marketing 52

Marketing Compliance Branding Regulation 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials